“Sapheon will significantly enhance Covidien’s global peripheral vascular business by providing additional treatment options for physicians and their patients who suffer from [chronic venous insufficiency],” said Brian Verrier, president of peripheral vascular businesses of Covidien, in a news release.
Financial terms of the acquisition were not disclosed.
More articles on acquisitions:
Premier to acquire Aperek for $48.5M
5 recent device, biotech company acquisitions
What Cerner’s acquisition of Siemens Health Services will mean for the health IT market
